Answers are grounded in this paper and cite their sources.
Traditional value assessment frameworks are challenged in comprehensively assessing the societal value new therapies bring to individuals with rare, progressive, genetic, fatal, neuromuscular diseases such as Duchenne muscular dystrophy (DMD). The objective of this study was to identify how value assessment frameworks may need to be adapted to measure the value to society of DMD therapies.
No takes yet. Share an insight, caveat, or question.
Fischer et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: